JP2010517544A - ヒトサイトメガロウイルス（ｈｃｍｖ）の組換え抗原 - Google Patents

ヒトサイトメガロウイルス（ｈｃｍｖ）の組換え抗原 Download PDF

Info

Publication number
JP2010517544A
JP2010517544A JP2009548617A JP2009548617A JP2010517544A JP 2010517544 A JP2010517544 A JP 2010517544A JP 2009548617 A JP2009548617 A JP 2009548617A JP 2009548617 A JP2009548617 A JP 2009548617A JP 2010517544 A JP2010517544 A JP 2010517544A
Authority
JP
Japan
Prior art keywords
seq
hcmv
antigen
nucleotide sequence
chimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009548617A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010517544A5 (cg-RX-API-DMAC7.html
Inventor
ニコーラ・ガルガノ
エリサ・ベゲット
アンドレア・スパドーニ
フランチェスカ・デ・パオリス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of JP2010517544A publication Critical patent/JP2010517544A/ja
Publication of JP2010517544A5 publication Critical patent/JP2010517544A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
    • G01N2333/04—Varicella-zoster virus
    • G01N2333/045—Cytomegalovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
JP2009548617A 2007-02-07 2008-02-05 ヒトサイトメガロウイルス（ｈｃｍｖ）の組換え抗原 Pending JP2010517544A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07101864 2007-02-07
PCT/EP2008/000876 WO2008095677A1 (en) 2007-02-07 2008-02-05 Recombinant antigens of human cytomegalovirus (hcmv)

Publications (2)

Publication Number Publication Date
JP2010517544A true JP2010517544A (ja) 2010-05-27
JP2010517544A5 JP2010517544A5 (cg-RX-API-DMAC7.html) 2011-03-24

Family

ID=38229391

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009548617A Pending JP2010517544A (ja) 2007-02-07 2008-02-05 ヒトサイトメガロウイルス（ｈｃｍｖ）の組換え抗原

Country Status (13)

Country Link
US (1) US20100068229A1 (cg-RX-API-DMAC7.html)
EP (1) EP2114991A1 (cg-RX-API-DMAC7.html)
JP (1) JP2010517544A (cg-RX-API-DMAC7.html)
KR (1) KR20090126256A (cg-RX-API-DMAC7.html)
CN (1) CN101605808A (cg-RX-API-DMAC7.html)
AU (1) AU2008213356A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0807095A2 (cg-RX-API-DMAC7.html)
CA (1) CA2677455A1 (cg-RX-API-DMAC7.html)
EA (1) EA200970731A1 (cg-RX-API-DMAC7.html)
IL (1) IL200187A0 (cg-RX-API-DMAC7.html)
MX (1) MX2009008248A (cg-RX-API-DMAC7.html)
SG (1) SG178761A1 (cg-RX-API-DMAC7.html)
WO (1) WO2008095677A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012005238A1 (ja) * 2010-07-07 2012-01-12 富士レビオ株式会社 ヒトサイトメガロウイルス感染の検出方法
JP2014504730A (ja) * 2011-01-18 2014-02-24 アメリカ合衆国 プリオンの増幅および検出のための方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012007489A (es) 2009-12-23 2012-11-29 4Antibody Ag Miembros enlazadores para citomegalovirus.
CN102816246B (zh) * 2012-09-04 2014-07-23 成都蓉生药业有限责任公司 一种人巨细胞病毒免疫原融合蛋白及其制备方法和用途
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
US11174322B2 (en) 2017-07-24 2021-11-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies and peptides to treat HCMV related diseases
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL60184A (en) * 1979-05-31 1984-05-31 Schering Ag Process for the specific cleavage of protein sequences from proteins
JPH01125328A (ja) * 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
CA2050425A1 (en) * 1990-09-03 1992-03-04 Yoshiaki Uda Pharmaceutical composition and its mucous use
RU2160120C2 (ru) * 1992-05-23 2000-12-10 Смитклайн Бичам Байолоджикалс С.А. Комбинированная вакцина на основе поверхностного антигена вируса гепатита в, способ ее получения и способ предупреждения инфекции гепатита в у человека
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
US5846806A (en) 1994-07-29 1998-12-08 American Cyanamid Company Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression
ES2187796T3 (es) * 1996-07-12 2003-06-16 Organon Teknika Bv Reactivo de peptidos que permiten la deteccion de citomegalovirus (cmv) humano.
US6306404B1 (en) * 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
AT408615B (de) * 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
WO2003010198A1 (en) 2001-07-26 2003-02-06 Kenton Srl Identification of specific tumour antigens by selection of cdna libraries with sera and use of said antigens in diagnostic techniques

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
JPN6012046635; Ｊ．　Ｖｉｒｏｌ．　Ｍｅｔｈｏｄｓ Ｖｏｌ．　９６, 2001, ｐ．　１５７-１７０ *
JPN6012046636; Ｊ．　Ｃｌｉｎ．　Ｍｉｃｒｏｂｉｏｌ． Ｖｏｌ．　３３，　Ｎｏ．　１０, 1995, ｐ．　２５３５-２５４２ *
JPN6012046637; Ｊ．　Ｖｉｒｏｌ．　Ｍｅｔｈｏｄｓ Ｖｏｌ．　６０, 1996, ｐ．　７３-８０ *
JPN6012046638; Ｍｉｃｒｏｂｉｏｌｏｇｉｃａ Ｖｏｌ．　１８, 1995, ｐ．　１-１２ *
JPN6012046640; Ｐｒｏｇｒｅｓｓ　ｉｎ　Ｃｙｔｏｍｅｇａｌｏｖｉｒｕｓ　Ｒｅｓｅａｒｃｈ , 1991, ｐ．　１９５-１９８ *
JPN6012046642; Ｊ．　Ｉｍｍｕｎｏｌ．　Ｍｅｔｈｏｄｓ Ｖｏｌ．　１７８, 1995, ｐ．　１-１２ *
JPN6012046644; Ｊ．　Ｖｉｒｏｌ． Ｖｏｌ．　７５，　Ｎｏ．　７, 2001, ｐ．　３２７７-３２９０ *
JPN6012046645; Ｊ．　Ｇｅｎ．　Ｖｉｒｏｌ． Ｖｏｌ．　８１, 2000, ｐ．　９９３-１０００ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012005238A1 (ja) * 2010-07-07 2012-01-12 富士レビオ株式会社 ヒトサイトメガロウイルス感染の検出方法
JP2012018051A (ja) * 2010-07-07 2012-01-26 Fujirebio Inc ヒトサイトメガロウイルス感染の検出方法
JP2014504730A (ja) * 2011-01-18 2014-02-24 アメリカ合衆国 プリオンの増幅および検出のための方法
JP2017134080A (ja) * 2011-01-18 2017-08-03 アメリカ合衆国 プリオンの増幅および検出のための方法

Also Published As

Publication number Publication date
EP2114991A1 (en) 2009-11-11
WO2008095677A1 (en) 2008-08-14
IL200187A0 (en) 2010-04-15
US20100068229A1 (en) 2010-03-18
EA200970731A1 (ru) 2010-02-26
AU2008213356A1 (en) 2008-08-14
CA2677455A1 (en) 2008-08-14
MX2009008248A (es) 2009-08-12
SG178761A1 (en) 2012-03-29
BRPI0807095A2 (pt) 2014-04-22
KR20090126256A (ko) 2009-12-08
CN101605808A (zh) 2009-12-16

Similar Documents

Publication Publication Date Title
JP2010517544A (ja) ヒトサイトメガロウイルス（ｈｃｍｖ）の組換え抗原
US6322794B1 (en) Seroreactive epitopes on proteins of human papillomavirus (HPV) 18
CN112125961B (zh) 牛病毒性腹泻-牛传染性鼻气管炎二联亚单位融合疫苗及其鉴定方法
EP1856159A1 (en) Chimeric recombinant antigens of toxoplasma gondii
JP2000514300A (ja) ヒトサイトメガロウイルス（ｃｍｖ）を検出するためのペプチド試薬
RU2202613C2 (ru) Иммуногенные пептиды вируса ящура
JPH0925295A (ja) エプスタイン−バールウイルスペプチド及び該ペプチドに対する抗体
JP4641695B2 (ja) 新規なｈｅｖ抗原性ペプチド及び方法
US20100112008A1 (en) Tuberculosis nucleic acids, polypeptides and immunogenic compositions
CN101124335B (zh) 高通量蛋白组学
US5837441A (en) Hantavirus-associated respiratory distress virus antigens
JP2008520210A (ja) Ｈｃｖｆタンパク質及びその使用
US6177080B1 (en) Polypeptides encoded by Kaposi sarcoma-associated herpes virus the use thereof in diagnosis and therapy
US7105165B2 (en) Mutant human hepatitis B viral strain and uses thereof
HK1135116A (en) Recombinant antigens of human cytomegalovirus (hcmv)
JP4619580B2 (ja) 抗体捕捉法による抗体の免疫学的測定方法
JP2004242599A (ja) Ｃｄ８＋細胞傷害性ｔリンパ球エピトープペプチド及びその用途
US20140004141A1 (en) Methods And Compositions Of Protein Antigens For The Diagnosis And Treatment Of Toxoplasma Gondii Infections And Toxoplasmosis
WO1999061909A2 (en) Methods and compositions for the detection of human herpesvirus
NO319698B1 (no) Hestearteritt-virus peptid eller peptidkonjugat omfattende en eller flere epitoper i stand til a fremkalle en immunrespons i dyr
JP2016503011A (ja) レプトスピラ症の診断および処置のための方法およびタンパク質抗原の組成物
CN115867312B (zh) 产生引发针对病毒的非病毒粒子组成衍生表位的人白细胞抗原i类限制性cd8 t细胞应答的疫苗组合物的方法
CN113493495B (zh) Eb病毒balf4蛋白的抗原表位
CN110967483B (zh) 恶性卡他热病毒的检测试剂盒、制备方法及其用途
WO2022195096A1 (en) Peptide and method for direct analysis of sars-cov-2 immune responses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120904

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130226